Payment overview · 2025
General Payments
$847.24
48 reported records · 12 companies
Healthcare provider profile · identity verified
Halah Al-Dadah, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1205043510
Verified facts
What the public records show
CMS Open Payments records show Halah Al-Dadah, M.D. received $847.24 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $290.18 | 34.2% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $199.58 | 23.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.41 | 7.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.59 | 7.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.77 | 6.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.39 | 6.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.04 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.95 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.21 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.14 | 2.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.08 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.90 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.24 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.08 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.80 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $131.20 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $131.20 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.34 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.31 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.59 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.77 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 985 | 289 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 107 |
| Lisinopril | Lisinopril | 316 | 91 |
| Meloxicam | Meloxicam | 314 | 96 |
| Omeprazole | Omeprazole | 299 | 90 |
| Trazodone Hcl | Trazodone Hcl | 283 | 63 |
| Gabapentin | Gabapentin | 276 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 79 |
| Losartan Potassium | Losartan Potassium | 258 | 72 |
| Alendronate Sodium | Alendronate Sodium | 257 | 76 |
| Alprazolam | Alprazolam | 253 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 59 |
| Metformin Hcl | Metformin Hcl | 219 | 69 |
| Fluoxetine Hcl | Fluoxetine Hcl | 207 | 51 |
| Simvastatin | Simvastatin | 189 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 41 |
| Tramadol Hcl | Tramadol Hcl | 146 | 63 |
| Bupropion Hcl Sr | Bupropion Hcl | 142 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 34 |
| Sertraline Hcl | Sertraline Hcl | 133 | 44 |
| Famotidine | Famotidine | 128 | 38 |
| Ozempic | Semaglutide | 128 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 34 |
| Glipizide | Glipizide | 122 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 26 |
| Clonazepam | Clonazepam | 117 | 20 |
| Potassium Chloride | Potassium Chloride | 114 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 31 |
| Carvedilol | Carvedilol | 103 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 23 |
| Eliquis | Apixaban | 95 | 19 |
| Allopurinol | Allopurinol | 92 | 24 |
| Ezetimibe | Ezetimibe | 92 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 91 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 24 |
| Furosemide | Furosemide | 90 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 23 |
| Montelukast Sodium | Montelukast Sodium | 82 | 21 |
| Clonidine Hcl | Clonidine Hcl | 81 | 26 |
| Methylprednisolone | Methylprednisolone | 77 | 70 |
| Lorazepam | Lorazepam | 73 | 21 |
| Glimepiride | Glimepiride | 66 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 21 |
| Buspirone Hcl | Buspirone Hcl | 60 | 21 |
| Aripiprazole | Aripiprazole | 59 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Jardiance | Empagliflozin | 58 | 11 |
| Celecoxib | Celecoxib | 56 | 22 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 55 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 13 |
| Prednisone | Prednisone | 44 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 29 |
| Finasteride | Finasteride | 41 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 13 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 13 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Azithromycin | Azithromycin | 30 | 28 |
| Diazepam | Diazepam | 29 | 11 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Estradiol | Estradiol | 26 | 14 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 14 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.24 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, KISUNLA, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error